Lenalidomide and second malignancies in myeloma patients.

Authors	Guy Pratt
Journal	The Lancet. Oncology (Lancet Oncol) Vol. 15 Issue 3 Pg. 253-4 (Mar 2014) ISSN: 1474-5488 [Electronic] England
PMID	24525201 (Publication Type: Journal Article, Comment)
Chemical References	Angiogenesis Inhibitors Thalidomide Lenalidomide
Topics	Angiogenesis Inhibitors (adverse effects) Humans Lenalidomide Multiple Myeloma (drug therapy) Neoplasms, Second Primary (chemically induced) Thalidomide (adverse effects, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!